Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 6/20 | 0.34 |
| ▸ | NOS2 | P35228 | 6/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 3/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | F12 | P00748 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952613 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2ATDP1KDM4E | |
| SCHEMBL304349 | 0.80 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2ATDP1KDM4E | |
| SCHEMBL30255032 | 0.80 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2ATDP1KDM4E | |
| SCHEMBL19489657 | 0.79 | KDM4E (0.39) | ALDH1A1KDM4EMAPTNOS3NOS2 | |
| SCHEMBL8131114 | 0.78 | NOS2 (0.37) | ALDH1A1MEN1KMT2ATDP1NOS3 | |
| SCHEMBL27776287 | 0.77 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2ATDP1KDM4E | |
| SCHEMBL25195292 | 0.77 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2ATDP1KDM4E | |
| SCHEMBL30356708 | 0.77 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2ATDP1KDM4E | |
| SCHEMBL5212066 | 0.77 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2ATDP1KDM4E | |
| SCHEMBL29956118 | 0.77 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2ATDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326748-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250152564-A1 | PROPYLENE KETONE-CONTAINING BIOINHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-05-15 | — | — | US | disclosed |
| WO-2025090809-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025021218-A1 | CYSTAL FORM OF PROPENONE-CONTAINING BIOLOGICAL INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2025-01-30 | — | — | WO | disclosed |
| CN-119371440-A | Salt containing acrylketone biological inhibitor, salt crystal form, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20240376076-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | DANA-FARBER CANCER INSTITUTE, INC. | 2024-11-14 | — | — | US | disclosed |
| CN-118574831-A | Biological inhibitor containing acrylketone, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-08-30 | — | — | CN | disclosed |
| CN-118401507-A | Inhibitors targeting ubiquitin-specific protease 7 (USP 7) | 丹娜法伯癌症研究院 | 2024-07-26 | — | — | CN | disclosed |
| EP-4373816-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | Dana-Farber Cancer Institute, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023143514-A1 | PROPYLENE KETONE-CONTAINING BIOINHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2023-08-03 | — | — | WO | disclosed |
| WO-2007043371-A1 | STILBENE DERIVATIVES, LIGHT-EMITTING ELEMENT AND LIGHT-EMITTING DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007043354-A1 | SPIROFLUORENE DERIVATIVE, MATERIAL FOR LIGHT-EMITTING ELEMENT, LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, AND ELECTRONIC DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007007885-A1 | CARBAZOLE DERIVATIVE, AND LIGHT EMITTING ELEMENT MATERIAL, LIGHT EMITTING ELEMENT, AND ELECTRONIC APPLIANCE OBTAINED USING THE SAME | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006081388-A2 | SUBSTITUTED PYRIDAZINYL-AND PYRIMIDINYL-QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006076646-A2 | HETEROARYL SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060111337-A1 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2006-05-25 | — | — | US | disclosed |
| WO-2006042289-A2 | SUBSTITUTED BIARYL QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-04-20 | — | — | WO | disclosed |
| EP-1644372-A2 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050070547-A1 | Substituted quinolin-4-ylamine analogues | NEUROGEN CORPORATION | 2005-03-31 | — | — | US | disclosed |
| WO-2005007652-A2 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152564-A1 | PROPYLENE KETONE-CONTAINING BIOINHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | CYP51A1, HSD17B7, CYP46A1 | ALDH1A1 522/4885MEN1 501/4885KMT2A 3172/4885 |
| US-20060111337-A1 | Substituted biaryl quinolin-4-ylamine analogues | PIGS, GPR52, GPR174 | ALDH1A1 882/4885MEN1 3786/4885KMT2A 2049/4885 |
| US-20240376076-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | USP7, USP47, USP2 | ALDH1A1 2692/4885MEN1 3697/4885KMT2A 1939/4885 |
| US-20050070547-A1 | Substituted quinolin-4-ylamine analogues | PIGS, HRH4, GPR52 | ALDH1A1 2379/4885MEN1 3807/4885KMT2A 1576/4885 |
| US-20250326748-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | ALDH1A1 3559/4885MEN1 3822/4885KMT2A 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.